CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: Preclinical studies have shown that ATRA-mediated CD38 upregulation can also enhance the immunomodulatory effects mediated by CD38 in AML and CML via reversal of tumor migration and NAD+ mediated resistance mechanisms, respectively [83,102].